Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 0.80 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9629498 | 0.91 | ALOX5 (0.71) | ALOX5 | |
| SCHEMBL9628717 | 0.89 | ALOX5 (1.00) | ALOX5TRPM8MEN1KMT2A | |
| SCHEMBL9628733 | 0.89 | ALOX5 (1.00) | ALOX5TRPM8 | |
| SCHEMBL11904930 | 0.89 | ALOX5 (0.71) | ALOX5TRPM8ALDH1A1KMT2A | |
| SCHEMBL9628647 | 0.88 | ALOX5 (0.69) | ALOX5TRPM8ALDH1A1 | |
| SCHEMBL9629437 | 0.85 | ALOX5 (1.00) | ALOX5TRPM8 | |
| SCHEMBL9628580 | 0.84 | ALOX5 (1.00) | ALOX5TRPM8MEN1ALDH1A1KMT2A | |
| SCHEMBL9629449 | 0.82 | ALOX5 (0.72) | ALOX5TRPM8ALDH1A1 | |
| SCHEMBL1954805 | 0.81 | ALOX5 (0.56) | ALOX5TRPM8MEN1ALDH1A1KMT2A | |
| SCHEMBL1954803 | 0.81 | ALOX5 (0.66) | ALOX5MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137193-B1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI SA (FR) | 2017-08-09 | — | — | EP | disclosed |
| US-9353100-B2 | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-8642603-B2 | Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof | SANOFI (FR) | 2014-02-04 | — | — | US | disclosed |
| WO-2012109398-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING HCV INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | WO | disclosed |
| US-20120207703-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING HCV INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20100075994-A1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2010-03-25 | — | — | US | disclosed |
| EP-2137193-A2 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | Sanofi-Aventis (FR) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008112483-A2 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | WO | disclosed |
| US-5124342-A | Antiinflammatory, antiarthritic agents; antiallergens; skin disorders | ABBOTT LABORATORIES (US) | 1992-06-23 | — | — | US | disclosed |
| EP-0457803-A4 | 4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS | — | 1991-12-04 | — | — | EP | disclosed |
| EP-0457803-A1 | 4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS | ABBOTT LABORATORIES (US) | 1991-11-27 | — | — | EP | disclosed |
| WO-1990009801-A1 | 4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS | ABBOTT LABORATORIES (US) | 1990-09-07 | — | — | WO | disclosed |
| WO-1990009381-A1 | 4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS | ABBOTT LABORATORIES (US) | 1990-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075994-A1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | GRM2, GRM1, GRIN2C | ALOX5 1162/4885TRPM8 756/4885MEN1 3249/4885 |
| US-20120207703-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING HCV INFECTIONS | PRSS1, SERPINB1, SPINT2 | ALOX5 1728/4885TRPM8 4098/4885MEN1 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.